Form 4: Tvardi Therapeutics Director Acquires Stock Options

Susan Shiff, a director at Tvardi Therapeutics, acquired stock options for 12,000 shares on April 17, 2025.

Summary

• On April 17, 2025, Susan Shiff, a director of Tvardi Therapeutics, acquired stock options.
• The options grant the right to buy 12,000 shares of common stock at an exercise price of $17.04 per share.
• The options vest in 12 equal quarterly installments over three years, starting on July 17, 2025, contingent upon continuous service.
• The options expire on April 16, 2035.

Sentiment

Score: 7

Explanation: The granting of stock options to a director is generally viewed as a positive sign, indicating confidence in the company's future. However, it's a routine event, so the sentiment is moderately positive.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a three-year commitment from the director, suggesting a long-term perspective on the company's prospects.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

stock options, director, Tvardi Therapeutics, beneficial ownership, Form 4, equity securities